Centessa Pharmaceuticals Maintains Buy Rating with $30 Target Price

Centessa Pharmaceuticals (CNTA) maintains a "Buy" rating and $30 target price from analyst Rudy Li of Chardan Capital. The rating and price target remain unchanged from the prior evaluation. The reiteration of the "Buy" rating and stable price target indicates confidence in Centessa Pharmaceuticals' current valuation and future prospects.

Centessa Pharmaceuticals (CNTA) has received a "Buy" rating from Chardan Capital with a $30 price target, according to a recent research note [1]. The rating and price target remain unchanged from the previous evaluation, indicating confidence in the company's current valuation and future prospects. This reiteration comes amidst a flurry of analyst attention and executive changes.

Chardan Capital, in their research note, highlighted the potential of Centessa Pharmaceuticals' pipeline, particularly the Orexin-2 receptor agonist, ORX750, which targets conditions like narcolepsy and idiopathic hypersomnia. The Phase 2 CRYSTAL-1 study results are expected in 2025, which could further bolster investor confidence in the company's pipeline.

In addition to the analyst endorsement, Centessa Pharmaceuticals has recently announced executive changes. The appointment of Raphael Deferiere as the new Chief Accounting Officer, effective May 27, 2025, indicates a period of strategic focus for the company. Deferiere brings a significant background in accounting, previously working as an Assurance Partner at Ernst & Young, LLP.

The stock has seen significant insider activity, with the Chief Business Officer, Gregory M. Weinhoff, selling 10,000 ordinary shares on July 25, 2025, for $155,598 [2]. The sale was executed under a Rule 10b5-1 trading plan adopted on May 22, 2024, and the shares were sold at prices ranging from $15.315 to $15.67, close to the current trading price of $15.41.

Centessa Pharmaceuticals has also seen an increase in institutional ownership, with hedge funds and investment management firms like Windmill Hill Asset Management Ltd, Aberdeen Group plc, HighMark Wealth Management LLC, and Platinum Investment Management Ltd increasing their stakes in the company [1].

The stock has a market capitalization of $2.21 billion, a PE ratio of -9.15, and a beta of 1.45. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37, and a quick ratio of 14.37. The stock has a 52-week low of $9.10 and a 52-week high of $19.09. Shares of NASDAQ:CNTA traded up $1.35 during trading on Wednesday, reaching $16.56.

References:
[1] https://www.marketbeat.com/instant-alerts/centessa-pharmaceuticals-nasdaqcnta-receives-buy-rating-from-chardan-capital-2025-07-30/
[2] https://za.investing.com/news/insider-trading-news/centessa-pharma-cnta-cbo-weinhoff-sells-155598-in-shares-93CH-3805831